BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 31844184)

  • 21. Enhanced anticancer activity of a combination of docetaxel and Aneustat (OMN54) in a patient-derived, advanced prostate cancer tissue xenograft model.
    Qu S; Wang K; Xue H; Wang Y; Wu R; Liu C; Gao AC; Gout PW; Collins CC; Wang Y
    Mol Oncol; 2014 Mar; 8(2):311-22. PubMed ID: 24388358
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Azacitidine improves antitumor effects of docetaxel and cisplatin in aggressive prostate cancer models.
    Festuccia C; Gravina GL; D'Alessandro AM; Muzi P; Millimaggi D; Dolo V; Ricevuto E; Vicentini C; Bologna M
    Endocr Relat Cancer; 2009 Jun; 16(2):401-13. PubMed ID: 19153211
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The Role of Crosstalk between AR3 and E2F1 in Drug Resistance in Prostate Cancer Cells.
    Xu J; Yang X; Deshmukh D; Chen H; Fang S; Qiu Y
    Cells; 2020 Apr; 9(5):. PubMed ID: 32354165
    [TBL] [Abstract][Full Text] [Related]  

  • 24. HIV-1 protease inhibitor, ritonavir: a potent inhibitor of CYP3A4, enhanced the anticancer effects of docetaxel in androgen-independent prostate cancer cells in vitro and in vivo.
    Ikezoe T; Hisatake Y; Takeuchi T; Ohtsuki Y; Yang Y; Said JW; Taguchi H; Koeffler HP
    Cancer Res; 2004 Oct; 64(20):7426-31. PubMed ID: 15492266
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The CHK1 inhibitor MU380 significantly increases the sensitivity of human docetaxel-resistant prostate cancer cells to gemcitabine through the induction of mitotic catastrophe.
    Drápela S; Khirsariya P; van Weerden WM; Fedr R; Suchánková T; Búzová D; Červený J; Hampl A; Puhr M; Watson WR; Culig Z; Krejčí L; Paruch K; Souček K
    Mol Oncol; 2020 Oct; 14(10):2487-2503. PubMed ID: 32579780
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Inhibition of hedgehog signaling improves the anti-carcinogenic effects of docetaxel in prostate cancer.
    Mimeault M; Rachagani S; Muniyan S; Seshacharyulu P; Johansson SL; Datta K; Lin MF; Batra SK
    Oncotarget; 2015 Feb; 6(6):3887-903. PubMed ID: 25682877
    [TBL] [Abstract][Full Text] [Related]  

  • 27. High efficacy of docetaxel with and without androgen deprivation and estramustine in preclinical models of advanced prostate cancer.
    Fizazi K; Sikes CR; Kim J; Yang J; Martinez LA; Olive MC; Logothetis CJ; Navone NM
    Anticancer Res; 2004; 24(5A):2897-903. PubMed ID: 15517894
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A combination of desmopressin and docetaxel inhibit cell proliferation and invasion mediated by urokinase-type plasminogen activator (uPA) in human prostate cancer cells.
    Sasaki H; Klotz LH; Sugar LM; Kiss A; Venkateswaran V
    Biochem Biophys Res Commun; 2015 Aug; 464(3):848-54. PubMed ID: 26182875
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Evidence of a novel docetaxel sensitizer, garlic-derived S-allylmercaptocysteine, as a treatment option for hormone refractory prostate cancer.
    Howard EW; Lee DT; Chiu YT; Chua CW; Wang X; Wong YC
    Int J Cancer; 2008 May; 122(9):1941-8. PubMed ID: 18183597
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cabazitaxel regimens inhibit the growth of prostate cancer cells and enhances the anti-tumor properties of PEDF with various efficacy and toxicity.
    Jarvis C; Nelius T; Martinez-Marin D; Sennoune SR; Filleur S
    Prostate; 2018 Sep; 78(12):905-914. PubMed ID: 29749077
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Additive naftopidil treatment synergizes docetaxel-induced apoptosis in human prostate cancer cells.
    Ishii K; Matsuoka I; Kajiwara S; Sasaki T; Miki M; Kato M; Kanda H; Arima K; Shiraishi T; Sugimura Y
    J Cancer Res Clin Oncol; 2018 Jan; 144(1):89-98. PubMed ID: 29098395
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Luteinizing hormone-releasing hormone receptor-targeted deslorelin-docetaxel conjugate enhances efficacy of docetaxel in prostate cancer therapy.
    Sundaram S; Durairaj C; Kadam R; Kompella UB
    Mol Cancer Ther; 2009 Jun; 8(6):1655-65. PubMed ID: 19509261
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Mebendazole induces apoptosis via Bcl-2 inactivation in chemoresistant melanoma cells.
    Doudican N; Rodriguez A; Osman I; Orlow SJ
    Mol Cancer Res; 2008 Aug; 6(8):1308-15. PubMed ID: 18667591
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Notch Pathway Inhibition Using PF-03084014, a γ-Secretase Inhibitor (GSI), Enhances the Antitumor Effect of Docetaxel in Prostate Cancer.
    Cui D; Dai J; Keller JM; Mizokami A; Xia S; Keller ET
    Clin Cancer Res; 2015 Oct; 21(20):4619-29. PubMed ID: 26202948
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Antitumor and antimetastatic activities of docetaxel are enhanced by genistein through regulation of osteoprotegerin/receptor activator of nuclear factor-kappaB (RANK)/RANK ligand/MMP-9 signaling in prostate cancer.
    Li Y; Kucuk O; Hussain M; Abrams J; Cher ML; Sarkar FH
    Cancer Res; 2006 May; 66(9):4816-25. PubMed ID: 16651437
    [TBL] [Abstract][Full Text] [Related]  

  • 36. In vivo CRISPR/Cas9 knockout screen: TCEAL1 silencing enhances docetaxel efficacy in prostate cancer.
    Rushworth LK; Harle V; Repiscak P; Clark W; Shaw R; Hall H; Bushell M; Leung HY; Patel R
    Life Sci Alliance; 2020 Dec; 3(12):. PubMed ID: 33033111
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Synergistic and antagonistic combinations of drugs in human prostate cancer cell lines in vitro.
    Budman DR; Calabro A; Kreis W
    Anticancer Drugs; 2002 Nov; 13(10):1011-6. PubMed ID: 12439335
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Dual CXCR4 and E-Selectin Inhibitor, GMI-1359, Shows Anti-Bone Metastatic Effects and Synergizes with Docetaxel in Prostate Cancer Cell Intraosseous Growth.
    Festuccia C; Mancini A; Gravina GL; Colapietro A; Vetuschi A; Pompili S; Ventura L; Delle Monache S; Iorio R; Del Fattore A; Fogler W; Magnani J
    Cells; 2019 Dec; 9(1):. PubMed ID: 31877673
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Gastric cancer cell death analyzed by live cell imaging of spheroids.
    Alzeeb G; Arzur D; Trichet V; Talagas M; Corcos L; Le Jossic-Corcos C
    Sci Rep; 2022 Jan; 12(1):1488. PubMed ID: 35087119
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Emerging Perspectives on the Antiparasitic Mebendazole as a Repurposed Drug for the Treatment of Brain Cancers.
    Meco D; Attinà G; Mastrangelo S; Navarra P; Ruggiero A
    Int J Mol Sci; 2023 Jan; 24(2):. PubMed ID: 36674870
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.